The emergence of WT1-specific T-cell responses following allogeneic T cell-depleted hematopoietic stem cell transplantation and low-dose donor lymphocyte infusions is associated with a graft- vs. -myeloma effect

Eleanor M Tyler1,2, and Guenther Koehne1,3,4

1Immunology and Microbial Pathogenesis Program; Weill Cornell Graduate School of Medical Sciences; New York, NY USA; 2Sloan-Kettering Institute; New York, NY USA; 3Weill Medical College of Cornell University; New York, NY USA; 4Adult Bone Marrow Transplant Service; Division of Hematologic-Oncology; Department of Medicine; Memorial Sloan-Kettering Cancer Center; New York, NY USA

Keywords: multiple myeloma, allogeneic stem cell transplantation, donor lymphocyte infusion, WT1-specific cytotoxic T cells, graft- vs. -myeloma effect

Allogeneic stem cell transplantation (alloSCT) remains a potentially curative option for multiple myeloma (MM) patients. Lower relapse rates have been reported for alloSCT as compared with autologous SCT, most likely due to the graft- vs. -myeloma (GvM) effect elicited by donor lymphocytes. However, both conventional and non-myeloablative allografts are associated with high rates of morbidity and mortality, most often resulting from graft- vs. -host disease (GVHD), post-transplantation infections or disease progression.1,2

The depletion of T cells from allografts prior to transplantation reduces GVHD and transplant-related mortality. However, this approach is believed to carry its own limitations, including a delayed immune reconstitution and a potentially greater risk of relapse due to the abrogation of immune GvM activity.3 On the other hand, allogeneic T cell-depleted hematopoietic SCT (alloTCD-HSCT), which does not require post-transplantation immunosuppressive therapy, provides a convenient platform for the subsequent implementation of immunotherapies, such as the infusion into patients of donor lymphocytes or antigen-specific T cells. In this setting, the lymphopenic environment of the host, as generated by pre-transplantation myelo/immunoablative conditioning, promotes the homeostatic proliferation of adoptively transferred T cells.4

An immune GvM effect has been documented in several clinical studies based on donor lymphocyte infusions (DLIs) post-alloSCT. Response rates of 40–60% have been reported in patients who received DLIs upon disease relapse after allogeneic transplantation. The ability of donor lymphocytes to mediate an effective antitumor response following allotransplantation is demonstrated by their capacity to frequently restore disease remission, and even induce continuous complete remission (CR) in some patients. However, the GvM responses observed in these studies were paralleled by a high incidence of acute and chronic GVHD. A strong association between GVHD and GvM effects has been observed, and GVHD has been suggested to constitute the major predictive factor for the of MM patients to DLI.5 This led to the initial assumption that the targets for GVHD and GvM activity are identical, in turn implying that a GvM effect cannot be achieved in the absence of a clinically significant GVHD.6 Recent results argue against this assumption and provide evidence for separate immune mechanisms being activated in the course of GVHD and GvM effects. Clinical remissions have indeed been documented in the absence of significant GVHD. Moreover, clearly distinguishable T-cell clones associated with GVHD and GvM effects have been identified by longitudinal TCR Vβ repertoire analyses post-DLI.7

One myeloma-associated antigen that may be the target of GvM effects is Wilms
may be of therapeutic benefits in patients with WT1-expressing myelomas and perhaps other WT1-expressing malignancies.

The absolute number of WT1-specific T cells that we detected in MM patients upon alloTCD-HSCT and DLI was significantly higher than that previously documented in leukemia patients receiving a vaccine targeting PR1 and WT1 (namely, 31 and 1 WT1-specific CD8+ T cells/μL peripheral blood, respectively). Such a marked gap in the magnitude of WT1-specific cytotoxic T lymphocyte (CTL) responses achieved in these settings may reflect intrinsic differences between leukemia and myeloma or may result from differences inherent to vaccination approaches as compared with the adoptive transfer of donor lymphocytes.

DLIs are not “immediate” therapeutic interventions. Time is indeed required for adoptively transferred T cells to encounter cognate antigens, become activated, proliferate in vivo and mediate antitumor effects. Such a delay between DLIs and the development of clinically meaningful T-cell responses should be taken into attentive consideration for selecting additional therapeutic regimens, in particular for choosing whether to administer chemotherapy or other therapeutic interventions that may exert immunosuppressive effects on adoptively transferred T cells. Sufficient time should indeed be allowed for DLIs to develop clinically significant T-cell responses, which may limit the applicability of this approach to rapidly progressive malignancies.

Conversely, the administration of immunomodulatory drugs such as lenalidomide prior to (or in combination with) DLIs facilitated the development of WT1-specific CTL responses in four of our patients who had not previously responded to DLIs alone. In this setting, the chemotherapy-induced death of myeloma cells is likely to promote the release of tumor-associated antigens and hence antigen uptake, processing and presentation by dendritic cells, overall favoring the development of tumor antigen-specific immune responses (Fig. 1).

Disclosure of Potential Conflict of Interest
No potential conflicts of interest were disclosed.
References

1. Gahrton G, Tura S, Ljungman P, Blåd J, Brandt L, Cavo M, et al. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol 1995; 13:1312-22; PMID:7751876

2. Krishnan A, Pasquini MC, Logan B, Stadtmueller EA, Vesole DH, Alyea E, et al.; Blood Marrow Transplant Clinical Trials Network (BMT CTN). Autologous hematopoietic stem-cell transplantation followed by autologous or allogeneic hematopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol 2011; 12:1195-203; PMID:21962393; http://dx.doi.org/10.1016/S1470-2045(11)70243-1

3. van Heijst JW, Ceberio I, Lipuma LB, Samilo DW, Wasilewski GD, Gonzales AM, et al. Quantitative assessment of T cell repertoire recovery after hematopoietic stem cell transplantation. Nat Med 2013; 19:372-7; PMID:23435170; http://dx.doi.org/10.1038/nm.3100

4. Muranski P, Boni A, Wrzesinski C, Citrin DE, Rosenberg SA, Childs R, et al. Increased intensity lymphodepletion and adoptive immunotherapy—how far can we go? Nat Clin Pract Oncol 2006; 3:608-81; PMID:17139318; http://dx.doi.org/10.1038/ncone0666

5. Lokhorst HM, Wu K, Verdonck LF, Laterveer LL, van de Donk NW, van Oers MH, et al. The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood 2004; 103:4652-4; PMID:14976044; http://dx.doi.org/10.1182/blood-2003-11-3862

6. Huff CA, Fuchs EJ, Noga SJ, O’Donnell PV, Ambinder RF, Diehl L, et al. Long-term follow-up of T cell-depleted allogeneic bone marrow transplantation in refractory multiple myeloma: importance of allogeneic T cells. Biol Blood Marrow Transplant 2003; 9:312-9; PMID:12766881; http://dx.doi.org/10.1016/S1083-8791(03)00075-2

7. Orsini E, Alyea EP, Schlossman R, Canning C, Soiffer RJ, Chillemi A, et al. Changes in T cell repertoire associated with graft-versus-tumor effect and graft-versus-host disease in patients with relapsed multiple myeloma after donor lymphocyte infusion. Bone Marrow Transplant 2000; 25:623-32; PMID:10734296; http://dx.doi.org/10.1038/sj.bmt.1702187

8. Rezvani K, Yong AS, Savani BN, Mielke S, Keyvanfar K, Gostick E, et al. Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia. Blood 2007; 110:1924-32; PMID:17505014; http://dx.doi.org/10.1182/blood-2007-03-076844

9. Tyler EM, Jungbluth AA, O’Reilly RJ, Koehne G. WT1-specific T-cell responses in high-risk multiple myeloma patients undergoing allogeneic T cell-depleted hematopoietic stem cell transplantation and donor lymphocyte infusions. Blood 2013; 121:308-17; PMID:23160468; http://dx.doi.org/10.1182/blood-2012-06-435040

10. Rezvani K, Yong AS, Mielke S, Savani BN, Musse L, Superara J, et al. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 2008; 111:236-42; PMID:17875804; http://dx.doi.org/10.1182/blood-2007-08-108241